Nafamostat (mesylate) – 50 mg

Brand:
Cayman
CAS:
82956-11-4
Storage:
-20
UN-No:
Non-Hazardous - /

Nafamostat is a serine protease inhibitor that is capable of inhibiting trypsin (a digestive system protease; Ki = 15 nM), tryptase (a mast cell protease; Ki = 95.3 pM), and additional proteases in the coagulation cascade including thrombin (Ki = 0.84 μM).{23663} In a mouse model of allergic asthma, a dose of 300 mg/kg nafamostat mesylate has been shown to inhibit serine proteolytic activity, to decrease circulating levels of eosinophils and lymphocytes in bronchoalveolar lavage fluid, and to reduce interleukin-13 and eotaxin production associated with antigen-induced airway eosinophilia and goblet cell hyperplasia.{23662}  

 

SKU: - Category:

Description

A serine proteases inhibitor that is capable of inhibiting trypsin (a digestive system protease; Ki = 15 nM), tryptase (a mast cell protease; Ki = 95.3 pM), and additional proteases in the coagulation cascade including thrombin (Ki = 0.84 μM); 300 mg/kg decreases the total number of eosinophils and lymphocytes in bronchoalveolar lavage fluid in a mouse model of allergic asthma


Formal name: 4-[(aminoiminomethyl)amino]-6-(aminoiminomethyl)-2-naphthalenyl ester-benzoic acid, dimethanesulfonate

Synonyms:  Coahibitor|FUT 175|Nafamastat

Molecular weight: 539.6

CAS: 82956-11-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Blood Coagulation Factors||Product Type|Biochemicals|Small Molecule Inhibitors|MMPs||Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Immunology & Inflammation|Allergy||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Immunology & Inflammation|Pulmonary Diseases|Asthma